Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | FABP7 | O15540 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296389 | 1.00 | EPHX1 (0.48) | EPHX1FABP7FABP5CA12CA1 | |
| SCHEMBL23587604 | 0.97 | EPHX1 (0.45) | EPHX1FABP7FABP5CA12CA1 | |
| SCHEMBL5953668 | 0.95 | EPHX1 (0.48) | EPHX1FABP7FABP5CA12CA1 | |
| SCHEMBL2678468 | 0.95 | EPHX1 (0.48) | EPHX1FABP7FABP5CA12CA1 | |
| SCHEMBL170007 | 0.95 | EPHX1 (0.48) | EPHX1FABP7FABP5CA12CA1 | |
| SCHEMBL24595803 | 0.95 | EPHX1 (0.48) | EPHX1FABP7FABP5CA12CA1 | |
| SCHEMBL11038809 | 0.95 | EPHX1 (0.48) | EPHX1FABP7FABP5CA12CA1 | |
| SCHEMBL17061159 | 0.95 | EPHX1 (0.48) | EPHX1FABP7FABP5CA12CA1 | |
| SCHEMBL17061158 | 0.95 | EPHX1 (0.48) | EPHX1FABP7FABP5CA12CA1 | |
| SCHEMBL27680260 | 0.95 | EPHX1 (0.48) | EPHX1FABP7FABP5CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112673000-B | 1H-indazole carboxamides as receptor interacting protein kinase 1 inhibitors (RIPK 1) | 百时美施贵宝公司 | 2024-10-18 | — | — | CN | claimed |
| US-8822724-B2 | Method for producing carboxylic acid amide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2599769-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | Sumitomo Chemical Company Limited (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123505-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED | 2013-05-16 | — | — | US | disclosed |
| CN-101506142-B | Process for production of trans-2,2-dimethyl- 3-formylcyclopropane carboxylic acid ester | SUMITOMO CO LTD | 2013-04-17 | — | — | CN | disclosed |
| CN-103025706-A | Method for producing carboxylic acid amide | SUMITOMO CHEMICAL CO | 2013-04-03 | — | — | CN | disclosed |
| CN-1832925-B | New P2X7 receptor avtagonists and their use | ASTRAZENECA AB | 2010-05-05 | — | — | CN | disclosed |
| EP-1633717-B1 | P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| CN-101506142-A | Process for production of trans-2,2-dimethyl- 3-formylcyclopropane carboxylic acid ester | SUMITOMO CHEMICAL CO (JP) | 2009-08-12 | — | — | CN | disclosed |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| CN-100341842-C | Process for production of formylcyclopropanecarboxylic ester compound | SUMITOMO CHEMICAL CO (JP) | 2007-10-10 | — | — | CN | disclosed |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| CN-1832925-A | New p2x7 receptor avtagonists and their use | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | CN | disclosed |
| CN-1761640-A | Process for production of carbonyl compounds | SUMITOMO CHEMICAL CO (JP) | 2006-04-19 | — | — | CN | disclosed |
| EP-1633717-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| CN-1681767-A | Method for manufacturing 2-(hydroxymethyl) cyclopropane carboxylic acid compound | SUMITOMO CHEMICAL CO (JP) | 2005-10-12 | — | — | CN | disclosed |
| CN-1668570-A | Process for producing formylcyclopropanecarboxylic acid ester compound | SUMITOMO CHEMICAL CO (JP) | 2005-09-14 | — | — | CN | disclosed |
| CN-1186310-C | Process for preparing 3,3-dimethyl-2-formoyl cyclopropane carboxylic ester | SUMITOMO CHEMICAL CO (JP) | 2005-01-26 | — | — | CN | disclosed |
| WO-2004106305-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| CN-1312244-A | Process for preparing 3,3-dimethyl-2-formoyl cyclopropane carboxylic ester | SUMITOMO CHEMICAL CO (JP) | 2001-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123505-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | HCAR2, NAAA, FAAH2 | EPHX1 1184/4885FABP7 3057/4885FABP5 2669/4885 |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | P2RX7, P2RX1, P2RX2 | EPHX1 612/4885FABP7 1809/4885FABP5 2367/4885 |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | P2RX7, P2RX1, P2RX2 | EPHX1 612/4885FABP7 1809/4885FABP5 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.